CIP
HRMY icon

Convergence Investment Partners’s Harmony Biosciences HRMY Stock Holding History

Convergence Investment Partners’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,682
Closed -$961K – 260
2025
Q4 		$961K Buy
+25,682
New +$844K 0.19% 169
2023
Q1 		– Sell
-2,656
Closed -$146K – 212
2022
Q4 		$146K Buy
+2,656
New +$146K 0.09% 186

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Convergence Investment Partners's HRMY Position: Q1 2026 in Review

Convergence Investment Partners sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 25,682 shares — an estimated $961K sold.

Convergence Investment Partners first reported a position in HRMY in Q4 2022 and held it in 2 quarters. The position peaked at $961K in Q4 2025. 311 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Convergence Investment Partners reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
  • Convergence Investment Partners sold 25,682 Harmony Biosciences shares in Q1 2026, an estimated $961K.
  • Convergence Investment Partners first reported a position in Harmony Biosciences in Q4 2022 and held it in 2 quarters.
  • Convergence Investment Partners's Harmony Biosciences position peaked at $961K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Convergence Investment Partners's 13F filing for Q1 2026, filed 7 May 2026.